Streetbeat News

Regulatory

BRTX

BioRestorative Therapies has received FDA clearance for an amendment to the Phase 2 clinical study protocol of BRTX-100, a significant step forward in its development process.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:46 am

LXEO

Lexeo Therapeutics' stock price increased following the announcement that its gene therapy candidate LX2006, aimed at treating Friedreich's ataxia cardiomyopathy, received FDA Fast Track designation.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:37 am

CYBN

Cybin announced the grant of an additional US patent supporting its CYB003 program for Major Depressive Disorder, potentially strengthening its intellectual property and therapeutic offering.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:35 am

LXEO

Lexeo Therapeutics has received FDA Fast Track Designation for LX2006, an AAV-based gene therapy candidate aimed at treating Friedreich's Ataxia Cardiomyopathy. This designation could accelerate the development and review process for LX2006, potentially bringing it to patients sooner.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:31 am

QQQ

SPY

TSLA

UNH

Wall Street anticipates a mixed open due to Middle-East tensions and rising bond yields, despite earnings optimism. UnitedHealth Group's earnings led to a rise in health benefit stocks, while tech stocks showed premarket weakness. The SPDR S&P 500 ETF Trust and Invesco QQQ ETF saw minor adjustments in premarket trading. Analysts suggest a potential reversal in sentiment, citing historical patterns of recovery post-streaks of declines. Upcoming economic data and Federal Reserve officials' speeches are in focus, alongside earnings reports from major companies.

Portfolio Pulse from Shanthi Rexaline

April 16, 2024 | 11:24 am

BLK

Markus Thielen of 10X Research, known for accurately predicting Bitcoin's rise, now forecasts a downturn in risk assets, including tech stocks and cryptocurrencies, due to persistent inflation and higher bond yields. Thielen has sold all tech stocks and reduced crypto holdings, citing poor Nasdaq performance and challenging interest rate cut expectations. The adjustment in Fed rate cut expectations and a high 10-year Treasury yield are diminishing the appeal of riskier investments. Despite a 42% YTD gain for Bitcoin and a 17% rise in the CoinDesk 20 Index, the market faces uncertainty, especially with the upcoming Bitcoin halving event.

Portfolio Pulse from Benzinga Neuro

April 16, 2024 | 11:09 am

NBIX

VYGR

Voyager Therapeutics and Neurocrine Biosciences plan to file an FDA Investigational New Drug application for their GBA1 program candidate in 2025. This step is crucial for advancing their collaborative efforts in developing treatments for diseases associated with GBA1 gene mutations.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:07 am

CYN

Cyngn has received a Notice of Allowance for its new patent, 17/812,072, aimed at enhancing autonomous vehicle solutions. This patent specifically addresses the generation of a compensated environmental model, focusing on overcoming the challenges of sensor motion and processing delays in data collection for autonomous vehicles.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 11:06 am

FCOM

META

XLC

Meta Platforms Inc (NASDAQ:META) introduces a 'Recent' filter on Threads for sorting search results by the most recent posts, aiming to enhance the user search experience. This feature is currently in a limited test phase. Despite the potential benefits, concerns over safety loopholes have been expressed. Additionally, Meta faces regulatory challenges in Turkey and the EU, impacting Threads' availability. Meta's stock has seen a 129% increase over the last 12 months, with exposure available through XLC and FCOM ETFs. META shares are currently trading lower by 0.39% at $498.30 in premarket trading.

Portfolio Pulse from Anusuya Lahiri

April 16, 2024 | 10:58 am

EIS

SPY

USO

Israel's War Cabinet is scheduled to meet on Tuesday to deliberate on the country's response to an Iranian attack, according to an Israeli official. The exact time of the meeting has not been disclosed.

Portfolio Pulse from Charles Gross

April 16, 2024 | 10:35 am